Evidence map›Paper›PMID 34202269›Full record

ArticleJournal of clinical medicine2021

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease.

Carla Giménez-Garzó, Alessandra Fiorillo, María-Pilar Ballester-Ferré, Juan-José Gallego, Franc Casanova-Ferrer, Amparo Urios, Salvador Benlloch, David Martí-Aguado, Teresa San-Miguel, Joan Tosca and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Role of ammonia in NAFLD: An unusual suspect.JHEP reports : innovation in hepatology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Carla Giménez-GarzóLaboratory of Neurobiology, Centro Investigación Príncipe Felipe, 46012 Valencia, Spain.
Alessandra FiorilloFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.
María-Pilar Ballester-FerréFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.ORCID 0000-0001-7177-5696
Juan-José GallegoFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.ORCID 0000-0003-4368-5284
Franc Casanova-FerrerFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.
Amparo UriosLaboratory of Neurobiology, Centro Investigación Príncipe Felipe, 46012 Valencia, Spain.
Salvador BenllochServicio de Digestivo, Hospital Arnau de Vilanova, 46015 Valencia, Spain.
David Martí-AguadoFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-4266-6076
Teresa San-MiguelDepartamento de Patología, Universidad Valencia, 46010 Valencia, Spain.ORCID 0000-0003-1892-6285
Joan ToscaFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.ORCID 0000-0003-1258-9513
María-Pilar RíosServicio de Digestivo, Hospital Arnau de Vilanova, 46015 Valencia, Spain.
Cristina MontónFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.
Lucía DurbánServicio de Digestivo, Hospital Arnau de Vilanova, 46015 Valencia, Spain.
Desamparados Escudero-GarcíaFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.
Luis AparicioDepartamento de Anatomía y Embriología, Universidad Valencia, 46010 Valencia, Spain.
Vicente FelipoLaboratory of Neurobiology, Centro Investigación Príncipe Felipe, 46012 Valencia, Spain.ORCID 0000-0003-3145-9538
Carmina MontoliuFundación Investigación Hospital Clínico, Instituto de Investigación Sanitaria, INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-4740-4788
INCLIVA Health Research Institute · ESHospital Clínico Universitario de Valencia · ESUniversitat de València · ESHospital Arnau de Vilanova · ESCentro de Investigacion Principe Felipe · ESInstituto de Salud Carlos III · ES

Funding

cofunded with European Regional Development Funds FIS PI18/00150; PROMETEOII/2018/051Consellería Educación Generalitat Valenciana PROMETEOII/2018/051Fundación Ramón Areces Fundación Ramón ArecesInstituto de Salud Carlos III, Spain FIS PI18/00150Ministerio de Ciencia e Innovación Spain SAF2017-82917-RPre-doctoral contracts from Generalitat Valenciana GRISOLIAP/2019/003; ACIF/2018/284, ACIF/2019/232Rio-Hortega contract from Instituto de Salud Carlos III CM19/00011
6 · The paper itself

Abstract

Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessing different neurological functions: PHES (Psychometric Hepatic Encephalopathy Score) battery, d2, Stroop, Oral SDMT (Symbol Digit Modalities Test), Digit Span, number-letter test, and bimanual and visual-motor coordination tests. NAFLD patients show impairment in attention, mental concentration, psychomotor speed, cognitive flexibility, inhibitory mental control, and working memory. We developed a new, rapid, and sensitive score based on the most affected parameters in NAFLD patients, unveiling that 32% of NAFLD show MCI. Prevalence was similar in NAFL (36%) or NASH (27%) patients, but lower in NAFLD than in cirrhosis (65%). MCI prevalence is significant in NAFLD patients. Psychometric testing is warranted in these patients to unveil MCI and take appropriate measures to reverse and prevent its progression.

Indexed as

NAFLNAFLDNASHneurological impairmentpsychometric score

Identifiers

PMID34202269
PMCPMC8268962
OpenAlexW3176648596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.